Immunology
Alumis secures $259m to develop therapies for immune dysfunction
Alumis has secured $259m in a Series C funding round to progress the development of its clinical-stage pipeline of oral…
Shifting the paradigm – novel approaches to amyotrophic lateral sclerosis therapy
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a swiftly advancing, fatal neurodegenerative condition marked by muscle…
AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront
AbbVie has signed a partnership and licensing agreement with OSE Immunotherapeutics for the latter’s monoclonal antibody OSE-230 in a deal…
AbbVie and Tentarix enter biologic development deal
AbbVie has signed a strategic partnership agreement with Tentarix Biotherapeutics to discover and develop new conditionally active, multi-specific biologic candidates…
Xyphos and Kelonia link for immuno-oncology drug development
Astellas subsidiary Xyphos Biosciences has entered a research partnership and licence agreement with Kelonia Therapeutics aimed at developing new immuno-oncology…
Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan
Swedish biotech Vicore Pharma has entered an exclusive licensing agreement for the Japanese rights for its idiopathic pulmonary fibrosis (IPF)…
China NMPA grants IND clearance for Fermion’s TYK2 JH2 inhibitor
The China National Medical Products Administration (NMPA) has granted clearance for the IND application of Guangzhou Fermion Technology’s FZ007-119. This…
AnaMar secures double orphan drug designation for systemic sclerosis drug
AnaMar has received orphan drug designations for its systemic sclerosis candidate AM1476 from the FDA and the EMA. The Swedish…
Inmagene to secure licence for two HUTCHMED drug candidates
Inmagene Biopharmaceuticals has exercised its option to secure an exclusive global and royalty-bearing licence for two HUTCHMED drug candidates, IMG-007…
Sanofi backs development of Graviton’s treatments for serious diseases
Graviton Bioscience has secured a strategic investment from Sanofi to develop a selective Rho/Rho-associated coiled coil [a structural motif in…